1OHR

VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Work: 0.200 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Kaldor, S.W.Kalish, V.J.Davies 2nd., J.F.Shetty, B.V.Fritz, J.E.Appelt, K.Burgess, J.A.Campanale, K.M.Chirgadze, N.Y.Clawson, D.K.Dressman, B.A.Hatch, S.D.Khalil, D.A.Kosa, M.B.Lubbehusen, P.P.Muesing, M.A.Patick, A.K.Reich, S.H.Su, K.S.Tatlock, J.H.

(1997) J.Med.Chem. 40: 3979-3985

  • DOI: 10.1021/jm9704098

  • PubMed Abstract: 
  • Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhi ...

    Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.


    Organizational Affiliation

    Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
ASPARTYLPROTEASE
A, B
99Human immunodeficiency virus 1Gene Names: v-1 PROTEASE
Find proteins for Q9Q288 (Human immunodeficiency virus 1)
Go to UniProtKB:  Q9Q288
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1UN
Query on 1UN

Download SDF File 
Download CCD File 
A
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
NELFINAVIR MESYLATE AG1343
C32 H45 N3 O4 S
QAGYKUNXZHXKMR-HKWSIXNMSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1UNKi: 2 nM (98) BINDINGDB
1UNKi: 2 nM BINDINGMOAD
1UNKi: 2 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Work: 0.200 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 52.040α = 90.00
b = 59.380β = 90.00
c = 61.670γ = 90.00
Software Package:
Software NamePurpose
X-PLORrefinement
X-PLORmodel building
X-PLORphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 1997-09-27 
  • Released Date: 1998-12-09 
  • Deposition Author(s): Davies II, J.F.

Revision History 

  • Version 1.0: 1998-12-09
    Type: Initial release
  • Version 1.1: 2008-03-03
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance